Bulletin
Investor Alert

Market Pulse Archives

Aug. 13, 2019, 8:44 a.m. EDT

Deciphera Pharmaceuticals stock more than doubles on heavy volume after positive trial data

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Deciphera Pharmaceuticals Inc. (DCPH)
  • X
    iShares Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Deciphera Pharmaceuticals Inc. /zigman2/quotes/203556943/composite DCPH -0.35% more than doubled toward a 14-month high in active premarket trading Tuesday, after the biopharmaceutical company said a phase 3 trial of its treatment of gastrointestinal stromal tumors (GIST) achieved its primary endpoint, paving the way for the company to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration. The stock rocketed 125% on volume of over 1.1 million shares ahead of the open, compared with the full-day average volume of about 293,000 shares. The primary endpoint of the study was improved progression free survival (PFS). A key secondary endpoint of objective response rate (ORR) was not statistically significant. The stock has lost 5.0% year to date through Monday, while the iShares Nasdaq Biotechnology ETF /zigman2/quotes/206189322/composite IBB -0.12% has gained 8.0% and the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.18% has climbed 15.0%.

/zigman2/quotes/203556943/composite
US : U.S.: Nasdaq
$ 33.89
-0.12 -0.35%
Volume: 263,256
Oct. 26, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.97 billion
Rev. per Employee
$120,249
loading...
/zigman2/quotes/206189322/composite
US : U.S.: Nasdaq
$ 160.04
-0.20 -0.12%
Volume: 2.16M
Oct. 26, 2021 4:00p
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,574.79
+8.31 +0.18%
Volume: 2.02B
Oct. 26, 2021 5:01p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.